0001140361-11-034290.txt : 20110627 0001140361-11-034290.hdr.sgml : 20110627 20110627144720 ACCESSION NUMBER: 0001140361-11-034290 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110627 DATE AS OF CHANGE: 20110627 EFFECTIVENESS DATE: 20110627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARACO PHARMACEUTICAL LABORATORIES LTD CENTRAL INDEX KEY: 0000887708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 382505723 STATE OF INCORPORATION: MI FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-31773 FILM NUMBER: 11932885 BUSINESS ADDRESS: STREET 1: 1150 ELIJAH MCCOY DR CITY: DETROIT STATE: MI ZIP: 48202 BUSINESS PHONE: 3138718400 MAIL ADDRESS: STREET 1: 1150 ELIJAH MCCOY DRIVE CITY: DETROIT STATE: MI ZIP: 48202 15-12B 1 form1512b.htm CARACO PHARMACEUTICALS 15-12(B) 6-27-2011 form1512b.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 15
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934


Commission File Number 1-31773

Caraco Pharmaceutical Laboratories, Ltd.
(Exact name of registrant as specified in its charter)
 
1150 Elijah McCoy Drive, Detroit, Michigan 48202        (313) 871-8400
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, no par value
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 
Rule 12g-4(a)(1)
S
  
 
Rule 12g-4(a)(2)
¨
  
 
Rule 12h-3(b)(1)(i)
¨
  
 
Rule 12h-3(b)(1)(ii)
¨
  
 
Rule 15d-6
S
  

Approximate number of holders of record as of the certification or notice date:  2


Pursuant to the requirements of the Securities Exchange Act of 1934, Caraco Pharmaceutical Laboratories, Ltd. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

DATE:  June 27, 2011
By:
/s/ GP. Singh
 
Name:
GP. Singh
 
Title:
Chief Executive Officer

Instruction:  This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934.  The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed.  It may be signed by an officer of the registrant, by counsel or by any other duly authorized person.  The name and title of the person signing the form shall be typed or printed under the signature.